Navigation Links
Exelixis Reports Positive Clinical Pharmacodynamics Data for PI3K/mTOR Inhibitor XL765 at ASCO
Date:5/31/2008

any dedicated to the discovery and development of novel small molecule therapeutics for the treatment of cancer and other serious diseases. The company is leveraging its fully integrated drug discovery platform to fuel the growth of its development pipeline, which is primarily focused on cancer. Currently, Exelixis' broad product pipeline includes investigational compounds in phase 2 and phase 1 clinical development. Exelixis has established strategic corporate alliances with major pharmaceutical and biotechnology companies, including GlaxoSmithKline, Bristol-Myers Squibb, Genentech, Wyeth Pharmaceuticals, and Daiichi-Sankyo. For more information, please visit the company's web site at http://www.exelixis.com.

Forward-Looking Statements

This press release contains forward-looking statements, including without limitation statements related to the future development and potential efficacy of XL765 and the timing of the initiation of clinical trials for XL765. Words such as "plan," "believe," and similar expressions are intended to identify forward-looking statements. These forward-looking statements are based upon our current plans, assumptions, beliefs and expectations. Forward-looking statements involve risks and uncertainties. Our actual results and the timing of events could differ materially from those anticipated in such forward- looking statements as a result of these risks and uncertainties, which include, without limitation, risks related to the potential failure of XL765 to demonstrate safety and efficacy in clinical testing, our ability to initiate and complete pivotal trials for XL765 at the referenced times; the timing and level of expenses associated with the growth of proprietary programs and other collaborations; the therapeutic and commercial value of XL765 and our other compounds; our relationship with our partners; and our ability to enter into new collaborations, continue existing co
'/>"/>

SOURCE Exelixis, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. GlaxoSmithKline Accelerates Review of Exelixis XL880
2. Exelixis Announces September 5 Webcast of Its 2007 IASLC Investor and Analyst Briefing
3. Exelixis Reports Top-Line Results of the Phase 2 Trial of XL784 in Patients With Proteinuria Associated With Diabetic Nephropathy
4. Updated Phase 1 Data for Exelixis XL184 Demonstrate Pharmacodynamic and Clinical Anti-Tumor Activity
5. Exelixis Reports XL647 Clinical Data at AACR-NCI-EORTC Conference
6. Interim Phase 2 Data for Exelixis XL880 Show Anti-Tumor Activity in Papillary Renal Cell Cancer
7. Phase 2 Trial Results for Exelixis XL784 Presented at the 2007 American Society of Nephrology Conference
8. Exelixis Presents Encouraging Phase 1 Data For XL019, A Novel Selective Inhibitor of JAK2
9. Exelixis Initiates Phase 1/2 Trial of XL184 in Patients With Non-Small Cell Lung Cancer
10. Exelixis Announces First Quarter 2008 Financial Results
11. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Research and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ... Consumables Market - Global Industry Analysis, Size, Share, Growth, ... their offering. (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ... are used on patients in order to treat dental ...
(Date:1/15/2014)... 2014 Massachusetts General Hospital (MGH), the Broad ... announced today that they have launched a strategic ... targets and develop novel therapies for inflammatory bowel ... worldwide. The MGH-Broad-Amgen collaboration brings together scientists with ...
(Date:1/15/2014)... an unprecedented effort to curb the spread of "superbugs" such as ... an advanced and portable UV germicidal lamp manufactured by MRSA-UV is ... In order to prevent EMS paramedics and transport patients ... Palm Beach Fire Rescue is the first in the ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
... Inc. (NYSE Amex: ANX ) today announced that ... at the 10th Annual BIOInvestor Forum Conference on Wednesday, October ... Cliff Salon at the Palace Hotel in San Francisco. ... and slide presentation on the ADVENTRX Pharmaceuticals web site at ...
... Innocoll, Inc. announced it has entered into a ... for CollaGUARD surgical adhesion barrier for the prevention of ... Dr. Michael Myers, President and CEO stated "This ... an increasingly important and dynamic market for medical products ...
Cached Medicine Technology:Innocoll Enters Partnership With Pioneer Pharma in China for the Distribution of CollaGUARD 2Innocoll Enters Partnership With Pioneer Pharma in China for the Distribution of CollaGUARD 3
(Date:4/17/2014)... IL, April 17, 2014-- Colic affects about one in ... for numerous pediatric visits during the first several months ... colic symptoms was showing promise; however, the April 1, ... (BMJ2014;348:g2107; Sung, Valerie) reported on a study, "Probiotics and ... L reuteri for infant colic did ...
(Date:4/17/2014)... from Boston University School of Medicine (BUSM) have ... consumption in an experimental model. The findings, reported ... Alcohol Abuse , may lead to more effective ... is one of the leading causes of illness ... negative economic impact by limiting the productivity of ...
(Date:4/17/2014)... (SACRAMENTO, Calif.) An international team led by researchers ... protein complex, which plays a key role in cell ... process. This is the first time the complex has ... could make cyclin B1/Cdk1 an excellent target to control ... medicine. The research was published online today in the ...
(Date:4/17/2014)... An international research team led by Cesar A. Arias, ... Center at Houston (UTHealth) has identified a new superbug ... The report appeared in the April 17 issue of ... The new superbug is part of a class of ... or MRSA, which is a major cause of hospital ...
(Date:4/17/2014)... to find a colored ribbon representing a disease. A pink ... color ribbon does one think of with lung cancer?, Although ... suffering from the disease, black may be the only one ... lung cancer patients, primarily smokers between the ages of 51 ... stigma often felt by these patients, the emotional toll it ...
Breaking Medicine News(10 mins):Health News:New study says probiotic use for infant colic is not effective in reducing symptoms 2Health News:BUSM researchers find anti-seizure drug may reduce alcohol consumption 2Health News:Dual role: Key cell division proteins also power up mitochondria 2Health News:New MRSA superbug emerges in Brazil 2Health News:Unraveling the 'black ribbon' around lung cancer 2
... news service, along,with its production and distribution partner, NewsProNet, ... to give viewers a daily update on the,latest medical ... Each weekday starting in January 2009, HealthDay TV ... Medical Officer Dr. Cynthia,Haines, who will give insight into ...
... (ECMO) Center at University Hospitals Rainbow Babies & ... Support Award from the Extracorporeal Life Support Organization ... centers offering ECMO for support of failing organ ... award recognizes centers demonstrating an exceptional commitment to ...
... Dec. 2 New research that delivers a,wealth of ... and,manufacturing is now available in the Best Practice Database, ... Best Practices,LLC. , ... these,pharmaceutical-focused studies, go to a landing page with links ...
... Cantel Medical Corp. (NYSE: CMN ) will hold ... first quarter ended October 31, 2008 on December 5, 2008 ... be Charles M. Diker, Chairman; Andrew A. Krakauer, President; Craig ... Malkin, President of Minntech Corporation. Minntech is a Cantel subsidiary. ...
... 2 Ingenious Med (IM) welcomes new CEO, S.,Hart ... solutions, with an extensive background as a leader in ... , Founder and ... the company,s success and development in all sectors, as ...
... it in first 3 months more likely to have respiratory ... mothers take folic acid (folate) during early pregnancy may have ... study. , Folate is recommended to reduce the risk of ... acid. , The researchers examined data on more than 32,000 ...
Cached Medicine News:Health News:HealthDay TV Launches 2Health News:HealthDay TV Launches 3Health News:Best Practice Database Adds Research Highlighting Effective Tactics of Sales Force and Manufacturing Groups in the Pharmaceutical Industry 2Health News:Cantel Medical Corp. to Hold Conference Call to Discuss Results for Its First Quarter Ended October 31, 2008 2Health News:Ingenious Med Hires New CEO to Maintain and Further Expand Company Development 2Health News:Folate in Early Pregnancy May Boost Wheezing in Baby 2
... intra-operative MR system is ... tool for radiologists and ... of the system is ... adjunct to standard neurosurgical ...
... Adhesive (Bioglue) is a two-component surgical ... albumin (BSA) and glutaraldehyde. The BSA ... bovine spongiform encephalopathy (BSE) free countries ... inactivates viruses. The solutions are dispensed ...
Avitene Microfibrillar Collagen Hemostat (MCH) is used in surgical procedures as an adjunct to hemostasis when control of bleeding by ligature or conventional procedures is ineffective or impractical...
... Prodisc design is based upon the ... natural spinal motion segment unit. Kinematics ... integrates the biomechanical and anatomical aspects ... concept: Three implant components utilizing proven ...
Medicine Products: